CD22 and lymphoma: Finally, the histone deacetylase inhibitor (HDACi) chidamide (Figure 1), which is capable of broadly modulating gene expression in B-cell lymphoma cell lines, was found to significantly upregulate CD22 expression in lymphoma cell lines in vitro and in vivo [27].